Rafael Holdings Inc (RFL)
1.81
-0.01
(-0.55%)
USD |
NYSE |
Apr 16, 13:06
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 44.50M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -5.70% |
| Valuation | |
| PE Ratio | 18.10 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 156.21 |
| Price to Book Value | 0.4241 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0162 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.72% |
Profile
| Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. |
| URL | https://www.rafaelholdings.com |
| Investor Relations URL | https://rafaelholdings.irpass.com/ |
| HQ State/Province | New Jersey |
| Sector | Real Estate |
| Industry | Real Estate Management & Development |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Jun. 13, 2024 (est.) |
| Last Earnings Release | Mar. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. |
| URL | https://www.rafaelholdings.com |
| Investor Relations URL | https://rafaelholdings.irpass.com/ |
| HQ State/Province | New Jersey |
| Sector | Real Estate |
| Industry | Real Estate Management & Development |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Jun. 13, 2024 (est.) |
| Last Earnings Release | Mar. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |